Treatment of patients with metastatic melanoma with bryostatin-1 - A phase II study

Melanoma Research

Volumn 9, Issue 6, 1999, Pages 599-606

  Gonzalez, R ^a   Ebbinghaus, S ^c   Henthorn, T K ^b   Miller, D ^c   Kraft, A S ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

Bryostatin 1; Metastatic melanoma; Pharmacology; Platelet activation

Indexed keywords

BRYOSTATIN; PROTEIN KINASE C;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG PROTEIN BINDING; FEMALE; HUMAN; MALE; MELANOMA; MYALGIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0033407483     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199912000-00010     Document Type: Article

References (25)

1. Pettit GR, Herald CL, Doubek DL, Herald DL, Arnold E, Clardy J. Isolation and structure of bryostatin 1. J Am Chem Soc 1982; 104: 6846-6848.
2. Schuchter LM, Esa AH, May WS, Laulis MK, Pettit GR, Hess AD. Successful treatment of murine melanoma with bryostatin 1. Cancer Res 1991; 51: 682-687.
3. Hornung RL, Pearson JW, Bechwith M, Longo DL. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res 1992; 52: 101-107.
4. Pettit GR, Day JF, Hartwell JL, Wood HB. Antineoplastic components of marine animals. Nature 1970; 227: 962-963.
5. Kraft AS, Smith JB, Berkow RL. Bryostatin, an activator of calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic HL-60 cells. Proc Natl Acad Sci USA 1986; 83: 1334-1338.
6. Lilly M, Brown C, Pettit G, Kraft AS. Bryostatin 1: a potential anti-leukemic agent for chronic myelomonocytic leukemia. Leukemia 1991; 5: 283-287.
7. Kraft AS, William F, Pettit GR, Lilly MB. Varied differentiation responses of human leukemias to bryostatin 1. Cancer Res 1989; 49: 1287-1293.
8. Mohammad RM, Varterasian ML, Almatchy VP, Hannoudi GN, Pettit GR, Al-katib A. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin-1. Clin Cancer Res 1998; 4: 1337-1343.
9. Jarvis WD, Fornari FA, Tombes RM, Erukulla RK, Bittman R, Schwartz GK, Dent P, Grant S. Evidence for involvement of mitogen-activated protein kinase, rather than stress-activated protein kinase, in potentiation of 1-beta-D-arabinofuranosylcytosine-induced apoptosis by interruption of protein kinase C signalling. Mol Pharmacol 1998; 54: 844-856.
10. Kraft AS, Woodley S, Pettit GR, Gao F, Coll JC, Wagner E Comparison of the antitumor activity of bryostatins 1, 5, and 8. Cancer Chemother Pharmacol 1996; 37: 271-278.
11. Philip PA, Rea D, Thavasu P, Carmichael J, Stuart NS, Rockett H, Talbot DC, Ganesan T, Pettit GR, Balkwill F, Harris AL. A phase I study of bryostatin 1: induction of interleukin-6 and tumour necrosis factor-alpha in vivo. J Natl Cancer Inst 1993; 85: 1812-1818.
12. Scheid C, Prendiville J, Jayson G, Crowther D, Fox B, Pettit GR, Stern PL. Immunomodulation in patients receiving intravenous bryostatin 1 in a phase I clinical study: comparison with effects of bryostatin 1 on lymphocyte function in vitro. Cancer Immunol Immunother 1994; 39: 223-230.
13. Berkow RL, Schlabach L, Dodson R, Benjamin WH, Pettit GR, Rustagi P, Kraft AS. In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity. Cancer Res 1993; 53: 2810-2815.
14. May WS, Sharkis SJ, Esa AH, Gebbia V, Kraft AS, Pettit GR, Sensebrenner LL. Antineoplastins are multipotential stimulators of human hematopoietic progenitor cells. Proc Natl Acad Sci USA 1987; 84: 8483-8487.
15. Sharkis SJ, Jones RJ, Bellis ML, Demetri GD, Griffin JD, Civin C, May WS. The action of bryostatin on normal human hematopoietic progenitors is mediated by accessory cell release of growth factors. Blood 1990; 76: 716.
16. Prendiville J, Crowther D, Thatcher N, Woll PJ, Fox BW, McGown A, Testa N, Stern P, McDermott R, Potter M, Pettit GR. A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer 1994; 68: 418-424.
17. Jayson GC, Crowther D, Prendiville J, McGown AT, Scheid C, Stern P, Young R, Brenchley P, Chang J, Owens S, Pettit GR. A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. Br J Cancer 1995; 72: 461-468.
18. Varterasian ML, Mohammad RM, Eilender DS, Kulburd K, Rodriguez DH, Pemberton PA, Pluda JM, Dan MD, Pettit GR, Chen BD, Al-katib AM. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J Clin Oncol 1998; 16: 56-62.
19. 31P magnetic resonance spectroscopic study. Br J Cancer 1995; 72: 998-1003.
20. Akiake H. A new look at the statistical model identification. IEEE Trans Automat 1974; 19: 716-723.
21. Kataria BK, Ved SA, Nicodemus HF, Hoy GR, Lea D, Dubois MY, Mandema JW, Shafer SL. The pharmacokinetics of propofol in children using three different data analysis approaches. Anesthesiology 1994; 80: 104-122.
22. Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987; 70: 307-315.
23. Markowitz JH, Kulkarni K, Goldschmidt-Clermont P, Kiefe CI, Rustagi P, Sekar P, Nanda N. Increased platelet activation and fibrinogen in Asian Indians. Eur Heart J 1998; 19: 720-726.
24. Propper DJ, Macaulay V, O'Byrne KJ, Braybrooke JP, Wilner SM, Ganensan TS, Talbot DC, Harris AL. A phase II study of bryostatin-1 in metastatic malignant melanoma. Br J Cancer 1998; 78: 1137-1341.
25. Grant S, Roberts J, Poplin E, Tombes MB, Kyle B, Welch D, Carr M, Bear HD. Phase Ib trial of bryostatin 1 in patients with refractory malignancies. Clin Cancer Res 1998; 4: 611-618.